NOVEL AGENTS FOR TREATMENT OF AILMENTS AND DYSFUNCTIONS

• US 20100204326A1
• Filed: 09/08/2008
• Published: 08/12/2010
• Est. Priority Date: 09/06/2007
• Status: Abandoned Application

• Current Assignee: Regain Biotechnology PVT Limited
• Original Assignee: Regain Biotechnology PVT Limited
• Inventors: D'Souza, Cletus J. M.
• Application Number:
  US12/678,189
• Publication Number:
  US 20100204326A1
• Time in Patent Office: Days
• US Class Current: 514/558
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis

Abstract

The present invention is related to the use of novel agents effective for differential killing of abnormal cells such as cancer cells without damaging or being toxic to normal cells. Further these agents may be used for treating a host of ailments including various types of cancers, skin diseases, prevention and reversal of ageing process, prevention of inflammatory reactions, cure of bacterial infections, cure of fungal infections, etc. The agents are prepared by air oxidation of natural oils optionally in the presence of a catalyst wherein the isolated agents have Iodine value 40-60% of the starting oil, Saponification value 20-60 higher than that of the starting oil, Peroxide value 2-3 times that of the starting oil. These agents on saponification and acidification yield free fatty acids and ether linked fatty acid dimmer wherein the dimmer also acts as an active.

Claims

1. Agents for the treatment of ailments and dysfunctions wherein

the agents are prepared by air oxidation of natural oils optionally in the presence of a catalyst wherein the isolated agents have Iodine value 40-60% of the starting oil, Saponification value 20-60 higher than that of the starting oil, Peroxide value 2-3 times that of the starting oil.

2. Agents of claim 1 which on saponification and acidification yields free fatty acids and ether linked fatty acid dimer.

3. A process for the preparation of the agents including the ether linked fatty acid dimer of claim 2, comprising steps of

ageing the oil in a vessel optionally layered with carbon particles,

allowing air oxidation with or without bubbling of air/oxygen optionally in the presence of catalysts to produce a red liquid of Iodine value 40-60% that of the starting oil, Saponification value 20-60 higher than that of the starting oil, Peroxide value 2-3 times that of the starting oil, and

separating the red liquid, optionally saponifying the red liquid, acidifying and isolating the ether linked fatty acid dimer.

4. The process for the preparation of agents including the ether linked fatty acid dimer of claim 3 wherein the red liquid in the oil is allowed to undergo air oxidation to produce a white precipitate having Iodine value of 40-60% that of the starting oil, saponification value 20-50 higher than that of the starting oil and Peroxide value of 40-60% of the red liquid.

5. The process of claim 3, wherein the oil is selected from the group consisting essentially of sunflower oil, safflower oil, ground nut oil, soybean oil, sesame oil and other unsaturated oils, preferably sesame oil.

6. The process of claim 3, wherein the oxidative process is catalysed by activated clays, metal oxides such as ferric oxide, lead oxide, mercury oxide, wherein lead oxide is the preferred choice, calcium octoate and potassium octoate.

7. The process of claims 3, wherein sesame oil with Iodine value of 60-70, saponification value of 220-230 and peroxide value of 10 and intrinsic viscosity of 0.035 on air oxidation produces a red liquid with iodine value of 30-40, saponification value of 250-270, peroxide value of 30-50 and Intrinsic viscosity of 0.05-0.07.

8. Agents including the ether linked fatty acid dimer of claim 2 wherein the agents at levels >

0.1 μ

g/ml exhibit cyto-toxicity on transformed cells like HeLa, KB and MFS-8 and up_to 100 μ

g/ml do not exhibit cyto-toxicity on HDCS and VERO.

9. Agents of claim 1 wherein the agents at levels of 0.1 μ

g/ml-100 μ

g/ml significantly control conditions of Yoshida sarcoma.

10. Agents of claim 1 to reduce the levels of mucopolysacchardies and glycoproteins specially in skin cells, increase levels of Δ

⁴ 3-oxo steroids and aid in the conversion of ³H progesterone to hydrocortisone.

11. Agents of claim 1 inhibit enzyme activities such as PLA₂ and lipoxygenase activity, growth of fungus such as aspergellus.

12. Compositions comprising the agents of claim 1 for conditioning of skin by reducing the levels of mucopolysacchardies and glycoproteins, increasing the levels of Δ

⁴ 3-oxo steroids and aiding in the conversion of ³H progesterone to hydrocortisone.

13. A medicament comprising the agents of claim 1 for treating diseased conditions in mammals such as uncontrolled cell growth, tumors, skin aliments, fungal infection, athlete'"'"'s foot infection, acne and atopic eczema.

14. A method of treating sarcoma using the medicament of claim 13 comprising administering a medicament, wherein the agents at levels >

0.1 μ

g/ml exhibit cyto-toxicity on transformed cells like HeLa₁ KB and MFS-8 and up to 100 μ

g/ml do not exhibit cyto-toxicity on HDCS and VERO.